Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Researchers find a new genetic vulnerability in acute myeloid leukemia

A study published in Nature Cell Biology reports a new vulnerability in acute myeloid leukemia (AML) that might lead to novel therapies to treat this cancer while minimizing harm to normal cells.

7 Aug 2026

Scalable education program protects transplant survivors from elevated skin cancer risk

Experts at City of Hope, one of the nation's largest and most advanced cancer research and treatment organizations, are shining a spotlight on the risk of skin cancer faced by hematopoietic cell transplant (HCT) survivors, as well as the need for early detection.

6 Aug 2026

Risk-adapted frameworks reshape pediatric neuroblastoma care

Neuroblastoma is the most common solid tumor outside the brain in children younger than five years old and accounts for about 15% of pediatric cancer deaths.

6 Aug 2026

Blocking ZFP36L2 protein may disrupt colorectal cancer metastatic growth

Digestion is hard on the cells that line the human gut, and they are constantly being shed and replaced. This renewal is driven by a population of tireless stem cells.

5 Aug 2026

Newly-discovered protein acts as off switch for human immune cells

Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body's immune response, a discovery that could help scientists develop new treatments that make cancer immunotherapies more effective.

3 Aug 2026

Midpregnancy herbicide exposure linked to increased preterm birth risk

Exposure to a widely used herbicide during the middle months of pregnancy may increase the chance of giving birth too early, before 37 weeks, a new study shows.

31 Jul 2026

Immature NK cells in donor cord blood can undermine CAR NK cell therapy activity

The composition of donor cord blood may play a critical role in the success of chimeric antigen receptor (CAR) natural killer (NK) cell therapies.

29 Jul 2026

Inherited genetics can influence safety and success of CAR-T cell therapy

Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma.

24 Jul 2026

MEK inhibition could limit T cell exhaustion and give a boost to immunotherapy

A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors.

23 Jul 2026

Chemotherapy leaves early genomic fingerprints in childhood tumors

Nearly half of childhood tumors treated with common types of chemotherapy showed detectable DNA changes linked to treatment within 18 months, according to a new international study led by The Hospital for Sick Children (SickKids).

23 Jul 2026

Senolytic drugs rejuvenate blood stem cells in sickle cell disease

Sickle cell disease causes premature aging of blood stem cells, which scientists may be able to address with a special class of drugs, according to a new study from St. Jude Children's Research Hospital.

22 Jul 2026

Midpregnancy herbicide exposure linked to increased risk of preterm birth

Exposure to a widely used herbicide during the middle months of pregnancy may increase the chance of giving birth too early, before 37 weeks, a new study shows.

22 Jul 2026

Dysregulation of immune regulator NF-κB drives major human diseases

NF‑κB controls genes involved in inflammation, immunity, cell survival, and proliferation. Triggered by cytokines (TNF‑α, IL‑1β), microbial products, or cellular stress, it translocates to the nucleus and induces pro‑inflammatory mediators.

13 Jul 2026

New analysis reveals biological features of treatment-resistant aggressive lymphoma

Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized.

3 Jul 2026

Scientists map how cellular senescence and stemness interact in disease

A new review was published in Volume 18 of Aging on May 30, 2026, titled "The love and hate relationship between cellular senescence and stemness."

29 Jun 2026

AACR report highlights unequal burden of cancer in the United States

The American Association for Cancer Research (AACR) today released its Cancer Disparities Progress Report 2026, a comprehensive analysis of the unequal burden of cancer in the United States.

24 Jun 2026

Scientists unlock molecular structure of key protein linked to cancer, neurological diseases

After nearly four decades of research, Mayo Clinic scientists have revealed the molecular structures of protein kinase C beta (PKCβ), a key protein linked to cancer and neurological diseases.

23 Jun 2026

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

Blocking a specific protein improves CAR T-cell therapy success in patients with blood cancers

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

15 Jun 2026

New all-oral regimen improves treatment convenience for AML patients

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.

3 Jun 2026